human vascular endothelial growth factor receptor 1 (VEGFR-1) fragment 129-228 comprising the second extracellular domain of the VEGF receptor (VEGFR-D2), [N<sup>196</sup>>A<sup>68</sup>]-variant, anti-(human vascular endothelial growth factor (VEGF) (1-100 in the current sequence) fused, via a (G4S)3 peptide linker (101-115), to gamma 1 heavy chain (116-563) [VH (Homo sapiens IGHV3-23*04 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo sapiens IGHG1*03 (CH1 (234-331), hinge (332-346), CH2 S<sup>414</sup>>A, E<sup>449</sup>>A, K<sup>450</sup>>A (347-456), CH3 (457-561), CHS (562-563)) (234-563)], (336-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 -IGKJ1*01, CDRKabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (342-342'', 345-345'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
NSCLC
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 65/ 100
Competitive context
1205 Active assets in the NSCLC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
d-0316 Betta Pharmaceuticals Co., Ltd. | Phase 2/3 | BBB |
Onartuzumab Hoffmann-La Roche | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
human vascular endothelial growth factor receptor 1 (VEGFR-1) fragment 129-228 comprising the second extracellular domain of the VEGF receptor (VEGFR-D2), [N<sup>196</sup>>A<sup>68</sup>]-variant, anti-(human vascular endothelial growth factor (VEGF) (1-100 in the current sequence) fused, via a (G4S)3 peptide linker (101-115), to gamma 1 heavy chain (116-563) [VH (Homo sapiens IGHV3-23*04 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo sapiens IGHG1*03 (CH1 (234-331), hinge (332-346), CH2 S<sup>414</sup>>A, E<sup>449</sup>>A, K<sup>450</sup>>A (347-456), CH3 (457-561), CHS (562-563)) (234-563)], (336-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 -IGKJ1*01, CDRKabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (342-342'', 345-345'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →